GeoSquare Logo GEOSQUARE

GSK Pharma Faces Rs 38.06 Crore Decree in Bombay Court Over Legacy Property Dispute

Published: December 22, 2025 | Category: real estate news
GSK Pharma Faces Rs 38.06 Crore Decree in Bombay Court Over Legacy Property Dispute

Mumbai: Drugmaker GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) has received a significant decree from the Court of Small Causes, Bombay, involving a total demand of Rs 38.06 crore. This demand is related to mesne profits for office premises that were previously used by Burroughs Wellcome (India) Limited, a company that merged with GSK Pharma over 24 years ago.

According to the disclosure made with the stock exchanges, the decree was dated 6 May 2025 and was received by the company on 2 November 2025. The order pertains to mesne profits amounting to ₹87.09 lakh, along with simple interest at the rate of 9% per annum from June 2001, aggregating to ₹37.19 crore, bringing the total demand to ₹38.06 crore.

The company clarified that the matter relates to office premises occupied more than 24 years ago by Burroughs Wellcome (India) Limited, prior to its merger with GlaxoSmithKline Pharmaceuticals Limited. GSK Pharma stated that it did not have prior records or logs of the case, which resulted in delayed confirmation of attribution and subsequent intimation to the exchanges.

In terms of impact, the company said it is currently assessing the decree and its implications on financial and operational activities. GSK Pharma added that it will take appropriate legal steps, including filing an appeal in due course, to safeguard its interests and mitigate any potential impact arising from the order.

The disclosure was formally addressed to BSE Limited and the National Stock Exchange of India Limited, and was signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary, on behalf of the company.

According to the regulatory filing submitted by GlaxoSmithKline Pharmaceuticals Limited, the decree arises from a long-pending legacy matter and does not involve any recent operational activity of the company. GSK Pharma remains committed to resolving the issue through legal channels and ensuring that its interests are protected.

Tags:

Stay Updated with GeoSquare WhatsApp Channels

Get the latest real estate news, market insights, auctions, and project updates delivered directly to your WhatsApp. No spam, only high-value alerts.

GeoSquare Real Estate News WhatsApp Channel Preview

Never Miss a Real Estate News Update — Get Daily, High-Value Alerts on WhatsApp!

Join Channels

Frequently Asked Questions

1. What is the total amount demanded by the Court of Small Causes, Bombay, from GSK Pharma?
The total amount demanded by the Court of Small Causes, Bombay, from GSK Pharma is Rs 38.06 crore, which includes mesne profits and simple interest.
2. What is the historical context of the property dispute involving GSK Pharma?
The property dispute involves office premises that were occupied more than 24 years ago by Burroughs Wellcome (India) Limited, which later merged with GSK Pharma.
3. How is GSK Pharm
planning to address this decree? A: GSK Pharma is currently evaluating the decree and its implications. They plan to file an appeal to safeguard their interests and mitigate any potential financial impact.
4. Who signed the disclosure on behalf of GSK Pharma?
The disclosure was signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary, on behalf of GSK Pharma.
5. Does this decree affect any recent operational activities of GSK Pharma?
No, the decree arises from a long-pending legacy matter and does not involve any recent operational activity of the company.